TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12194641

Group type: EXPERIMENTAL
Intervention: Airmax inhaler (100 micrograms BID)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Turbuhaler (100 micrograms BID)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Airmax inhaler
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Airmax and Turbuhaler
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Airmax
Number of subjects: 25
Study: 9468205

Group type: EXPERIMENTAL
Intervention: Optimal DCA
Number of subjects: 1000

Group type: COMPARATOR
Intervention: PTCA
Number of subjects: 1000
Study: 7607931

Group type: EXPERIMENTAL
Intervention: 14.4 Gy of total body irradiation (TBI)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 13.2 Gy of total body irradiation (TBI)
Number of subjects: 44
Study: 1724191

Group type: EXPERIMENTAL
Intervention: Low Molecular Weight Heparin (LMWH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydroxyethyl Starch (HES)
Number of subjects: 0
Study: 364626

Group type: EXPERIMENTAL
Intervention: 40 mg prednisolone once daily (single dose)
Number of subjects: 45

Group type: COMPARATOR
Intervention: 10 mg prednisolone four times a day (divided doses)
Number of subjects: 45
Study: 31446990

Group type: EXPERIMENTAL
Intervention: Oral vinorelbine and cisplatin (OVP)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Etoposide and cisplatin (EP)
Number of subjects: 140
Study: 27941383

Group type: COMPARATOR
Intervention: Fibrin glue
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Autologous blood
Number of subjects: 111
Study: 27140800

Group type: EXPERIMENTAL
Intervention: Lapatinib powder for oral suspension
Number of subjects: 144

Group type: COMPARATOR
Intervention: Commercial tablet formulation of lapatinib
Number of subjects: 144
Study: 23916965

Group type: EXPERIMENTAL
Intervention: Web-based cognitive behavioral therapy (CBT) with therapist support for 6 weeks using the MoodGYM program.
Number of subjects: 106
Study: 21810677

Group type: EXPERIMENTAL
Intervention: MVAC chemotherapy (methotrexate, vinblastine, doxorubicin, and cisplatin) for three cycles
Number of subjects: 521

Group type: COMPARATOR
Intervention: Observation (control group for p53-positive patients)
Number of subjects: 521
Study: 19803020

Group type: EXPERIMENTAL
Intervention: High dose chlorpheniramine plus chloroquine (6 mg + 12 mg/day for 7 days in children ≤ 5 years; 8 mg + 18 mg/day for 7 days in those >5 years) plus chloroquine 10 mg/kg daily for 3 days
Number of subjects: 99

Group type: COMPARATOR
Intervention: Higher dose chlorpheniramine plus chloroquine (50% higher dose) plus chloroquine 10 mg/kg daily for 3 days
Number of subjects: 99
Study: 17268417

Group type: EXPERIMENTAL
Intervention: Active group supplemented daily with 6 mg lutein combined with vitamins and minerals.
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo group (n=10).
Number of subjects: 25
Study: 15115982

Group type: EXPERIMENTAL
Intervention: Hypothermia (34 degrees C)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Normothermia (37 degrees C)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 144
Study: 11893049

Group type: EXPERIMENTAL
Intervention: Gluma One Bond
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: UniFil Bond
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Mega Bond
Number of subjects: 30

Group type: COMPARATOR
Intervention: Vaseline coating (additional group)
Number of subjects: 30
Study: 9457393

Group type: EXPERIMENTAL
Intervention: recombinant interleukin‐2 (rIL‐2) therapy (8‐18 x 10(6) IU/m2 x 5 days) by continuous intravenous infusion with a 72‐hour rest period between each cycle, followed by subcutaneous maintenance rIL‐2 therapy at lower doses for 5 days/month
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: rIL‐2 therapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: no treatment
Number of subjects: 24
Study: 7870534

Group type: EXPERIMENTAL
Intervention: 45 mph simulated pitch speed
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 70 mph simulated pitch speed
Number of subjects: 44
Study: 3129390

Group type: EXPERIMENTAL
Intervention: Enoxacin (400 mg bd)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Amoxycillin (1,000 mg tid)
Number of subjects: 43
Study: 30134549

Group type: EXPERIMENTAL
Intervention: Natural dietary supplement (NDS) containing Curcuma longa, silymarin, guggul, chlorogenic acid and inulin
Number of subjects: 0

Group type: COMPARATOR
Intervention: High fat diet (HFD) untreated mice
Number of subjects: 0
Study: 27004663

Group type: EXPERIMENTAL
Intervention: Marker placement laser device
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Barefoot with three different tape conditions
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Barefoot
Number of subjects: 38
Study: 25776067

Group type: EXPERIMENTAL
Intervention: OPT-CON therapy (Optimised concomitant therapy) - esomeprazole (40 mg b.d.), amoxicillin (1 g b.d.), clarithromycin (500 mg b.d.), and metronidazole (500 mg b.d.) for 14 days
Number of subjects: 777

Group type: COMPARATOR
Intervention: OPT-TRI therapy (Optimised triple therapy) - esomeprazole (40 mg b.d.), amoxicillin (1 g b.d.), and clarithromycin (500 mg b.d.) for 14 days
Number of subjects: 777

Group type: EXPERIMENTAL
Intervention: OPT-CON therapy
Number of subjects: 777

Group type: COMPARATOR
Intervention: OPT-TRI therapy
Number of subjects: 777
Study: 23574458

Group type: EXPERIMENTAL
Intervention: 1 g tranexamic acid intravenously over 10 min before elective cesarean section
Number of subjects: 740

Group type: COMPARATOR
Intervention: Control group (no tranexamic acid)
Number of subjects: 740
Study: 20105396

Group type: EXPERIMENTAL
Intervention: Acupuncture (SP6, KI3, KI6, BL60, LI4, and acupressure on BL67)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 84
Study: 19134445

Group type: EXPERIMENTAL
Intervention: Acupressure wrist bands
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo bands
Number of subjects: 18

Group type: COMPARATOR
Intervention: Standard care treatment with no bands
Number of subjects: 18
Study: 15059051

Group type: EXPERIMENTAL
Intervention: Sheepskin mattress overlay for the duration of hospital stay (218 patients)
Number of subjects: 441

Group type: COMPARATOR
Intervention: Usual treatment as determined by ward staff (223 patients)
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Sheepskin group
Number of subjects: 441
Study: 11481298

Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam 6.0/0.75 g q12h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam 8.0/1.0 g q12h
Number of subjects: 0
Study: 9745797

Group type: EXPERIMENTAL
Intervention: Underprediction information condition
Number of subjects: 40

Group type: COMPARATOR
Intervention: Correct information condition
Number of subjects: 40
Study: 8149358

Group type: EXPERIMENTAL
Intervention: levodopa methyl ester (ME)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Sinemet CR
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: half the dose of ME together with a halved tablet of Sinemet CR
Number of subjects: 11
Study: 2966825

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 152

Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 152
Study: 29956199

Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (active treatment), 8 sessions of 5 minutes each over 4 weeks
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 40
Study: 26984534

Group type: EXPERIMENTAL
Intervention: web-based Kanker Nazorg Wijzer intervention
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Behavior-related modules
Number of subjects: 432

Group type: COMPARATOR
Intervention: Control group (usual cancer aftercare)
Number of subjects: 432
Study: 24785885

Group type: EXPERIMENTAL
Intervention: Kakkonto Extract‐A, 6 g/day
Number of subjects: 340

Group type: COMPARATOR
Intervention: Pabron Gold‐A, 3.6 g/day
Number of subjects: 340
Study: 22269590

Group type: EXPERIMENTAL
Intervention: Carotid plaque ultrasonographic screening (US group)
Number of subjects: 536

Group type: COMPARATOR
Intervention: No screening (control group)
Number of subjects: 536
Study: 20580604

Group type: EXPERIMENTAL
Intervention: Probiotic fermented milk beverage containing Lactobacillus casei strain Shirota (40 billion bacterial cells/bottle for 4 weeks, 1 bottle/day)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Probiotic fermented milk beverage containing Lactobacillus casei strain Shirota
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 17909399

Group type: EXPERIMENTAL
Intervention: Simulated sea-level (SL) conditions
Number of subjects: 20

Group type: COMPARATOR
Intervention: Local normoxic hypobaria
Number of subjects: 20
Study: 16228839

Group type: EXPERIMENTAL
Intervention: Subcutaneous gentamycin-collagen implant
Number of subjects: 80

Group type: COMPARATOR
Intervention: Collagen implant without antibiotics (placebo)
Number of subjects: 80
Study: 11303543

Group type: EXPERIMENTAL
Intervention: Support by the Diabetes Service
Number of subjects: 246

Group type: COMPARATOR
Intervention: Conventional general practice care
Number of subjects: 246
Study: 9129563

Group type: EXPERIMENTAL
Intervention: Oral codeine administration
Number of subjects: 10

Group type: COMPARATOR
Intervention: Oral placebo administration
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pharmacokinetic parameters of morphine
Number of subjects: 10
Study: 8035452

Group type: EXPERIMENTAL
Intervention: Normative education
Number of subjects: 3077

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 3077
Study: 3313489

Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM) program
Number of subjects: 2000
Study: 30705369

Group type: EXPERIMENTAL
Intervention: Hypertonic saline nasal irrigation and gargling (HSNIG)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 68
Study: 26542990

Group type: EXPERIMENTAL
Intervention: HG-Reg (handgrip-Regadenoson)
Number of subjects: 60
Study: 26010359

Group type: EXPERIMENTAL
Intervention: Zamzee intervention
Number of subjects: 182

Group type: COMPARATOR
Intervention: Passive control group
Number of subjects: 182

Group type: COMPARATOR
Intervention: Active control group (commercially available active videogame)
Number of subjects: 182
Study: 23585559

Group type: EXPERIMENTAL
Intervention: Prednisolone (20 mg for 6 weeks, 10 mg for 1 week, 5 mg for 1 week)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 21643711

Group type: EXPERIMENTAL
Intervention: Spatial working memory task
Number of subjects: 745

Group type: EXPERIMENTAL
Intervention: Verbal working memory task
Number of subjects: 745

Group type: COMPARATOR
Intervention: Matched no‐memory control tasks
Number of subjects: 745
Study: 19139319

Group type: EXPERIMENTAL
Intervention: Vasopressin (20 IU per CPR cycle) plus epinephrine (1 mg per CPR cycle)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Stress-dose hydrocortisone sodium succinate (300 mg daily for 7 days maximum)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Isotonic sodium chloride solution placebo plus epinephrine (1 mg per CPR cycle)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 100
Study: 16738026

Group type: EXPERIMENTAL
Intervention: Dialectical self-definition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gender (Women)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Global self-views
Number of subjects: 0
Study: 15475020

Group type: EXPERIMENTAL
Intervention: School-based nutrition intervention in Alabama
Number of subjects: 2106

Group type: EXPERIMENTAL
Intervention: School-based nutrition intervention in Minnesota
Number of subjects: 2106
Study: 11774703

Group type: EXPERIMENTAL
Intervention: Mild walking exercise (30 minutes a day)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no walking exercise)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Mild walking exercise
Number of subjects: 52
Study: 9203725

Group type: EXPERIMENTAL
Intervention: Trivalent oral poliovirus vaccine (OPV) administered in the rainy season
Number of subjects: 46

Group type: COMPARATOR
Intervention: Trivalent oral poliovirus vaccine (OPV) administered in other seasons
Number of subjects: 46
Study: 8278816

Group type: EXPERIMENTAL
Intervention: Combination therapy (auranofin and methotrexate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Auranofin
Number of subjects: 0
Study: 30561227

Group type: EXPERIMENTAL
Intervention: CYP11B2 (‐344T) allele in hypertensive patients
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: CYP11B2 ‐344TT genotype
Number of subjects: 100
Study: 29967525

Group type: EXPERIMENTAL
Intervention: Maternal vitamin B12 intake during infancy
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Vitamin B12 status in infancy
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Maternal vitamin B12 status
Number of subjects: 331
Study: 27095529

Group type: EXPERIMENTAL
Intervention: Optimal PAPP (PAPP >0.50)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Nonoptimal PAPP (PAPP ≤0.50)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: PAPP as a continuous variable
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Logistic regression model with pulmonary capillary wedge pressure, creatinine, and nonoptimal PAPP
Number of subjects: 175
Study: 24726174

Group type: EXPERIMENTAL
Intervention: Intravenous TXA (500 mg)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Joint irrigation with TXA (3 g in 100 cc saline)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: TXA injection through the drain (1.5 g)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no TXA)
Number of subjects: 200
Study: 21422238

Group type: EXPERIMENTAL
Intervention: AR9281 (250 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AR9281 (500 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple doses of AR9281 (100-400 mg every 8 hours)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19904559

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bevacizumab group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 18242008

Group type: EXPERIMENTAL
Intervention: Nicotine patch and nicotine gum
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 103
Study: 16183617

Group type: EXPERIMENTAL
Intervention: 16-item Rey memory test combined with WAIS-III Digit Span test
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: 15-item Rey memory test combined with WAIS-III Digit Span test
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Combination of total score from the 16-item test with digits forward span
Number of subjects: 96

Group type: COMPARATOR
Intervention: Any single test score or any other combination of digit span score with a Rey score
Number of subjects: 96
Study: 12544991

Group type: EXPERIMENTAL
Intervention: Intravenous erythromycin (500 mg)
Number of subjects: 36
Study: 10551192

Group type: EXPERIMENTAL
Intervention: Practice Assessment Report (PAR)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Continuing Medical Education Plan (CMEP)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control group (PAR only)
Number of subjects: 56
Study: 8694158

Group type: EXPERIMENTAL
Intervention: 50% nitrous oxide in oxygen
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 70% nitrous oxide in oxygen
Number of subjects: 24
Study: 1997806

Group type: EXPERIMENTAL
Intervention: Correct feedback (greater left hemisphere low frequency activity)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Incorrect feedback (greater right hemisphere low frequency activity)
Number of subjects: 24

Group type: COMPARATOR
Intervention: No feedback control
Number of subjects: 24
Study: 6217886

Group type: EXPERIMENTAL
Intervention: MOF plus streptozotocin (MOF-Strep)
Number of subjects: 75

Group type: COMPARATOR
Intervention: MOF
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: MOF-Strep
Number of subjects: 75
Study: 30068817

Group type: EXPERIMENTAL
Intervention: Alirocumab (75 mg every 2 weeks, increased to 150 mg if week 8 LDL-C was above predefined limits)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study: 29903578

Group type: EXPERIMENTAL
Intervention: Removable brace
Number of subjects: 44

Group type: COMPARATOR
Intervention: Cast
Number of subjects: 44
Study: 26843796

Group type: EXPERIMENTAL
Intervention: Positive affect and self-affirmation intervention with motivational interviewing
Number of subjects: 238

Group type: COMPARATOR
Intervention: Education control group
Number of subjects: 238
Study: 24484726

Group type: EXPERIMENTAL
Intervention: Roflumilast 500 μg once-daily
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 23111049

Group type: EXPERIMENTAL
Intervention: Positive Feedback (PF)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Negative Feedback (NF)
Number of subjects: 25
Study: 19606092

Group type: EXPERIMENTAL
Intervention: Transdermal melatonin (MEL) delivery during daytime
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral melatonin (MEL)
Number of subjects: 0
Study: 17697058

Group type: EXPERIMENTAL
Intervention: IDF criteria
Number of subjects: 3042

Group type: COMPARATOR
Intervention: NCEP criteria
Number of subjects: 3042
Study: 15353873

Group type: EXPERIMENTAL
Intervention: Enalapril (10-20 mg daily)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Eprosartan (400-800 mg daily)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: High dose eprosartan or enalapril
Number of subjects: 42
Study: 11593101

Group type: EXPERIMENTAL
Intervention: Irbesartan (150-300 mg once daily)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Atenolol (50-100 mg once daily)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (placebo run-in period)
Number of subjects: 34
Study: 9724827

Group type: COMPARATOR
Intervention: EN-9527 (standard medical nutritional)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: EN-9528 (renal nutritional)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: EN-9529 (renal nutritional with fructooligosaccharides)
Number of subjects: 79
Study: 7988779

Group type: EXPERIMENTAL
Intervention: Sitostanol ester (3 g daily)
Number of subjects: 11
Study: 2594908

Group type: EXPERIMENTAL
Intervention: Pentobarbital (30 mg per dose)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pentobarbital
Number of subjects: 12
Study: 31325604

Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine (CHM)
Number of subjects: 342

Group type: COMPARATOR
Intervention: Non-Chinese herbal medicine (non-CHM)
Number of subjects: 342
Study: 29037224

Group type: EXPERIMENTAL
Intervention: Maternal BMI < 25 kg/m2
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Maternal BMI > 30 kg/m2
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Mothers giving birth to infants with macrosomia
Number of subjects: 327

Group type: EXPERIMENTAL
Intervention: Mothers giving birth to infants classified as large-for-gestational-age (LGA)
Number of subjects: 327
Study: 25634811

Group type: EXPERIMENTAL
Intervention: BOOCS program participants (1,565 males and 742 females)
Number of subjects: 21626

Group type: COMPARATOR
Intervention: Nonparticipant comparative obese controls (1,230 males and 605 females)
Number of subjects: 21626
Study: 24144896

Group type: COMPARATOR
Intervention: GSK1265744 (5 mg)
Number of subjects: 59

Group type: COMPARATOR
Intervention: GSK1265744 (30 mg)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 59
Study: 21762230

Group type: EXPERIMENTAL
Intervention: Provided ED process information (n = 336)
Number of subjects: 1011

Group type: EXPERIMENTAL
Intervention: Provided ED process information plus predicted service delivery times (n = 333)
Number of subjects: 1011

Group type: COMPARATOR
Intervention: Usual care (n = 342)
Number of subjects: 1011

Group type: EXPERIMENTAL
Intervention: Waiting room time (every 10-minute increase)
Number of subjects: 1011

Group type: EXPERIMENTAL
Intervention: Patients aged 35 years and older
Number of subjects: 1011
Study: 19430944

Group type: EXPERIMENTAL
Intervention: Low-intensity exercise with slow CON contractions (5-1)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Low-intensity exercise with slow ECC contractions (1-5)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Low-intensity exercise with slow CON and ECC contractions (3-3)
Number of subjects: 9

Group type: COMPARATOR
Intervention: High-intensity exercise at normal velocity (1-1)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Low-intensity exercise with slow ECC action (1-5)
Number of subjects: 9
Study: 16528149

Group type: EXPERIMENTAL
Intervention: Multidisciplinary team-based planning with nurse practitioner/physician management
Number of subjects: 1207

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1207
Study: 14632537

Group type: EXPERIMENTAL
Intervention: Tezosentan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11076819

Group type: EXPERIMENTAL
Intervention: Mental stress
Number of subjects: 18

Group type: COMPARATOR
Intervention: No mental stress
Number of subjects: 18
Study: 8996851

Group type: EXPERIMENTAL
Intervention: Piperacillin (PPR) 60 mg/kg infusion every 8 hours
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Modified dosage pattern of Piperacillin (PPR) 60 mg/kg every 4 hours
Number of subjects: 8
Study: 1444872

Group type: EXPERIMENTAL
Intervention: Diltiazem (180 mg for the first 48 hours, adjusted to 240 mg until the 7th day)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Propranolol (120 mg for the first 48 hours, adjusted to 160 mg until the 7th day)
Number of subjects: 56
Study: 4050895

Group type: EXPERIMENTAL
Intervention: Intrauterine saline amnioinfusion
Number of subjects: 96

Group type: COMPARATOR
Intervention: Noninfusion (control group)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Intrauterine saline amnioinfusion (in nulliparous patients)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Noninfusion (control group in nulliparous patients)
Number of subjects: 96
Study: 30857954

Group type: EXPERIMENTAL
Intervention: Local cryostimulation (−160 °C) for 6 minutes on the extensor-flexor muscles of the dominant arm
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (rested in a thermo-neutral room at 22 ± 0.5 °C)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Local cryostimulation
Number of subjects: 50